Catecholaminergic polymorphic ventricular tachycardia (PCVT) is a rare, 
congenital ventricular tachyarrhythmia which occurs in the setting of adrenergic 
activation. It potentially leads to syncope and/or sudden cardiac death (SCD). 
PCVT represents one of the most dangerous congenital ion channel diseases. 
Mutations of the ryanodine receptor gene (RYR2), the calsequestrin gene (CASQ2), 
and the triadin gene (TRDN) have been identified as an underlying correlate. 
β-Blockers are employed as therapy and are sometimes combined with class IC 
antiarrhythmic drugs, or calcium antagonists of the verapamil type. ICD 
implantation is recommended in case of persisting syncope in the presence of 
β-blocker therapy or survived SCD. Left thoracic sympathectomy represents a 
subsidiary interventional therapy for individual cases. In addition, 
modifications of the patient's lifestyle including avoidance of physical stress 
and heart rates> 120/min are recommended.